Deal watch: Infinity and Intellikine to develop oral PI3K inhibitors for inflammatory diseases.
D000284:Administration, Oral; D000818:Animals; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D000081082:Phosphoinositide-3 Kinase Inhibitors
D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors
Nat Chem Biol. 2010 Feb;6(2):117-24
20081827